' 
SCIENTIFIC SCORE
Possibly Effective
Based on 13 Researches
7.2
USERS' SCORE
Good
Based on 23 Reviews
8.9
Supplement Facts
Serving Size: 1 Softgel
Amount Per Serving
%DV
Vitamin A (from Retinyl Palmitate and Fish Liver Oil)
7,500 mcg
833%
Top Medical Research Studies
8
Retinoic acid enhances glioma treatment
Retinoic acid-induced alterations enhance eATP-mediated anti-cancer effects in glioma cells: Implications for P2X7 receptor variants as key players.
Purinergic signaling's dual role
We investigated how retinoic acid (RA), a derivative of vitamin A, could influence cancer treatment, particularly in glioma, a type of brain tumor. Previous attempts to use RA as a therapeutic option were inconclusive, so we aimed to explore its effects alongside extracellular ATP (eATP) to harness their combined potential.
Our experiments examined two human glioma cell lines, M059K and M059J, to see how they responded to RA-based differentiation. Notably, this process led to changes in the expression of a receptor called P2X7 and reduced the activity of enzymes that break down nucleotides. These modifications contributed to a significant decrease in cell proliferation and migration abilities, as well as an increased sensitivity to the effects of eATP.
Specifically, we found that in the presence of eATP, cell viability decreased by up to 40% in RA-treated M059K cells and 20% in M059J cells. Migration capabilities of the cells were reduced by as much as 60% when exposed to a specific concentration of ATP, showing that the P2X7 receptor plays a major role in mediating these effects.
Our observations suggest that combining retinoic acid with eATP can have anti-cancer benefits by influencing purinergic signaling pathways in glioma cells. This points to the need for further exploration of P2X7 receptor variants as potential therapeutic targets for treating glioma.
Our experiments examined two human glioma cell lines, M059K and M059J, to see how they responded to RA-based differentiation. Notably, this process led to changes in the expression of a receptor called P2X7 and reduced the activity of enzymes that break down nucleotides. These modifications contributed to a significant decrease in cell proliferation and migration abilities, as well as an increased sensitivity to the effects of eATP.
Specifically, we found that in the presence of eATP, cell viability decreased by up to 40% in RA-treated M059K cells and 20% in M059J cells. Migration capabilities of the cells were reduced by as much as 60% when exposed to a specific concentration of ATP, showing that the P2X7 receptor plays a major role in mediating these effects.
Our observations suggest that combining retinoic acid with eATP can have anti-cancer benefits by influencing purinergic signaling pathways in glioma cells. This points to the need for further exploration of P2X7 receptor variants as potential therapeutic targets for treating glioma.
Read More
5
Vitamins A's potential in cancer
The therapeutic potential of vitamins A, C, and D in pancreatic cancer.
Study shows promise for vitamin A
We explored the potential benefits of vitamin A as a complementary treatment for pancreatic cancer, particularly in pancreatic ductal adenocarcinoma (PDAC), which remains one of the deadliest forms of cancer. Our investigation revealed that vitamin A, alongside vitamins C and D, showed promising signs of inhibiting tumor cell growth in laboratory settings and preclinical models.
The effectiveness of vitamin A seems to be linked to its ability to activate specific nuclear receptors that influence gene activity. This could make tumor cells more susceptible to other therapies, potentially improving treatment outcomes.
However, while initial findings are encouraging, there's a strong need for further research in clinical settings to better understand how vitamin A works on a cellular level and to determine the most effective ways to incorporate it into standard care. With PDAC patients facing limited treatment options and short survival times, exploring such avenues could be vital in enhancing patient care and outcomes.
The effectiveness of vitamin A seems to be linked to its ability to activate specific nuclear receptors that influence gene activity. This could make tumor cells more susceptible to other therapies, potentially improving treatment outcomes.
However, while initial findings are encouraging, there's a strong need for further research in clinical settings to better understand how vitamin A works on a cellular level and to determine the most effective ways to incorporate it into standard care. With PDAC patients facing limited treatment options and short survival times, exploring such avenues could be vital in enhancing patient care and outcomes.
Read More
4
Retinoic acid reduces neuroblastoma growth
Short-term effects of retinoic acid on the proliferation of SH-SY5Y cells via mitophagy and apoptosis.
Relevant to cancer treatment analysis
We explored how retinoic acid, a form of vitamin A, affects the growth of SH-SY5Y neuroblastoma cells, which is a type of cancer common in children. Our goal was to understand whether this compound could improve outcomes in neuroblastoma by influencing cell proliferation and death processes like apoptosis and mitophagy.
To examine this, we treated the cells with varying concentrations of retinoic acid and observed its impact over 24, 48, and 72 hours. We determined that an optimal concentration was 10 μM at the 24-hour mark, where we saw significant changes in several genes related to cell growth and death.
Interestingly, we observed a decrease in gene expressions associated with cell proliferation while genes linked to cell death were upregulated. Specifically, vital factors like Ki-67 were down, and others like Parkin and cytochrome C were increased, indicating that retinoic acid may promote cell death rather than support cell growth in neuroblastoma cells.
Overall, our findings suggest that while retinoic acid shows potential in improving certain neurodegeneration parameters, it simultaneously reduces the proliferation of neuroblastoma cells through mechanisms like mitophagy and apoptosis. Hence, its effects might be more complex and emphasize the need for further research before considering it a straightforward treatment option.
To examine this, we treated the cells with varying concentrations of retinoic acid and observed its impact over 24, 48, and 72 hours. We determined that an optimal concentration was 10 μM at the 24-hour mark, where we saw significant changes in several genes related to cell growth and death.
Interestingly, we observed a decrease in gene expressions associated with cell proliferation while genes linked to cell death were upregulated. Specifically, vital factors like Ki-67 were down, and others like Parkin and cytochrome C were increased, indicating that retinoic acid may promote cell death rather than support cell growth in neuroblastoma cells.
Overall, our findings suggest that while retinoic acid shows potential in improving certain neurodegeneration parameters, it simultaneously reduces the proliferation of neuroblastoma cells through mechanisms like mitophagy and apoptosis. Hence, its effects might be more complex and emphasize the need for further research before considering it a straightforward treatment option.
Read More
Most Useful Reviews
9.5
Improved gastritis
The required amount of Vitamin A varies significantly depending on individual circumstances. Those with dry eye, asthma, gastrointestinal issues, or a family history of cancer may require more. I gradually increased my intake to 100,000 units for a year, which cleared my persistent red sore gastritis, eliminating the need for medication.
Read More
9.5
Healed cystitis
Vitamin A has been fantastic for me. Despite a family history of cancer, I was cautious about overdosing, so I started at 25,000 and moved to 50,000. My cystitis improved, corns softened, and irregular bleeding stopped. If I can heal without surgery, I will continue striving for 75,000 daily!
Read More
9.5
Improved eyesight
Following a high-protein, low-sugar diet and taking Vitamin A has improved my eyesight, and my wife's presbyopia has resolved. We take these supplements to prevent cancer due to a familial history, which is particularly important for our health.
Read More
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 13 Researches
7.2
- All Researches
9.5
Vitamin A shows promise in APL
Zebrafish modeling of atypical PML-RARA isoform from acute promyelocytic leukemia patient and its implications for clinical treatment.
Focus on ATRA's efficacy
We constructed a zebrafish model to explore how a unique version of the PML-RARA protein, linked to acute promyelocytic leukemia (APL), might respond to treatment with all-trans retinoic acid (ATRA). This model allowed us to examine whether ATRA, a derivative of vitamin A, could be effective for patients with atypical APL characteristics.
In our findings, we observed that the response of the new PML-RARA isoform to ATRA treatment was similar to classical isoforms seen in the condition. We also found that ATRA worked well in this model, leading to favorable results for the treated patient, who reached complete remission shortly after starting therapy with ATRA and arsenic trioxide (ATO).
These results highlight the promising potential of vitamin A derivatives in cancer treatment, especially in various forms of APL. It's encouraging to see that ATRA can lead to substantial recovery, further supporting its use in clinical settings alongside other therapies.
In our findings, we observed that the response of the new PML-RARA isoform to ATRA treatment was similar to classical isoforms seen in the condition. We also found that ATRA worked well in this model, leading to favorable results for the treated patient, who reached complete remission shortly after starting therapy with ATRA and arsenic trioxide (ATO).
These results highlight the promising potential of vitamin A derivatives in cancer treatment, especially in various forms of APL. It's encouraging to see that ATRA can lead to substantial recovery, further supporting its use in clinical settings alongside other therapies.
Read More
9.5
Promising APL treatment outcomes observed
Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia.
Combination treatment evaluated; ATRA included
We aimed to understand the effectiveness of a combination treatment involving all-trans retinoic acid (ATRA), arsenic trioxide (ATO), and gemtuzumab ozogamicin (GO) for patients with acute promyelocytic leukemia (APL). This was a phase 2 trial involving newly diagnosed APL patients, where ATRA and ATO were used to induce remission.
The results were promising, as we observed a complete remission rate of 93.8% among the participants. Furthermore, 97.1% of those who achieved remission had no measurable residual disease, indicating a strong initial response to the treatment regimen.
Over a median follow-up of about 62 months, the 5-year survival rates were also impressive, with event-free survival at 92.4%, disease-free survival at 93.6%, and overall survival at 93.1%. We noted some side effects, including elevated liver enzymes and infections, but there were no severe complications like veno-occlusive disease.
While the study highlights the benefits of ATRA in this combination treatment, we must clarify that we cannot specifically isolate the effect of vitamin A, as it was part of a broader therapeutic approach. Nonetheless, the combination of ATRA with other agents showed significant success in treating APL, reinforcing the importance of multifaceted cancer therapies.
The results were promising, as we observed a complete remission rate of 93.8% among the participants. Furthermore, 97.1% of those who achieved remission had no measurable residual disease, indicating a strong initial response to the treatment regimen.
Over a median follow-up of about 62 months, the 5-year survival rates were also impressive, with event-free survival at 92.4%, disease-free survival at 93.6%, and overall survival at 93.1%. We noted some side effects, including elevated liver enzymes and infections, but there were no severe complications like veno-occlusive disease.
While the study highlights the benefits of ATRA in this combination treatment, we must clarify that we cannot specifically isolate the effect of vitamin A, as it was part of a broader therapeutic approach. Nonetheless, the combination of ATRA with other agents showed significant success in treating APL, reinforcing the importance of multifaceted cancer therapies.
Read More
9
Fenretinide shows promise against AML
Fenretinide targets GATA1 to induce cytotoxicity in GATA1 positive Acute Erythroid and Acute Megakaryoblastic Leukemic cells.
Addresses targeted treatment in AML
We observed that certain types of Acute Myeloid Leukemia (AML), specifically acute erythroleukemia and acute megakaryocytic leukemia, have a concerningly short median survival and limited effective treatment options. Our exploration focused on understanding the role of the transcription factor GATA1, which is crucial for the survival of cells in these leukemia subtypes. Remarkably, we discovered that a compound known as Fenretinide (or 4-HPR), a synthetic derivative of vitamin A, can target and induce loss of GATA1 in these AML cells.
As we delved into the study, we found that treating M6 AML cells with low concentrations of 4-HPR led to significant cytotoxic effects, akin to reducing GATA1 levels through genetic methods. This indicates that 4-HPR could act similar to a targeted therapy, directly impacting the survival of these cancer cells. Further, we were encouraged to see that 4-HPR not only performed effectively on its own but also enhanced the effectiveness of existing treatments like Azacytidine and Venetoclax, which typically struggle against drug resistance.
Our findings suggest that 4-HPR might represent a promising therapeutic avenue for patients with M6 and M7 AML, paving the way for its potential inclusion as a standard treatment option in the near future. The safety profile of Fenretinide, established through numerous clinical trials, further strengthens the case for its application in the combat against these aggressive forms of leukemia.
As we delved into the study, we found that treating M6 AML cells with low concentrations of 4-HPR led to significant cytotoxic effects, akin to reducing GATA1 levels through genetic methods. This indicates that 4-HPR could act similar to a targeted therapy, directly impacting the survival of these cancer cells. Further, we were encouraged to see that 4-HPR not only performed effectively on its own but also enhanced the effectiveness of existing treatments like Azacytidine and Venetoclax, which typically struggle against drug resistance.
Our findings suggest that 4-HPR might represent a promising therapeutic avenue for patients with M6 and M7 AML, paving the way for its potential inclusion as a standard treatment option in the near future. The safety profile of Fenretinide, established through numerous clinical trials, further strengthens the case for its application in the combat against these aggressive forms of leukemia.
Read More
9
Acyclic Retinoid aids lung cancer treatment
Acyclic Retinoid Inhibits the EGFR/AKT Signaling Pathway and Cancels Cisplatin-resistant Cell Characteristics.
Moderate relevance; vitamin A context
This study delved into the effects of a compound called Acyclic Retinoid, which is derived from vitamin A, on lung cancer and its resistance to a common chemotherapy drug, cisplatin. We explored how Acyclic Retinoid could impact key signaling pathways that contribute to the growth and spread of non-small cell lung cancer (NSCLC), a prevalent and deadly form of the disease. Our focus was on how ACR affected the signals associated with the cancer progression, particularly the EGFR/AKT pathway, which is often overactive in lung cancer situations.
We treated various types of lung cells—including standard cancer cell lines and those resistant to cisplatin—with ACR, both alone and alongside cisplatin. By examining cell viability, apoptosis (the process of programmed cell death), and changes in important cellular signals, we gathered insightful data on the potential of this treatment. The results were promising; ACR inhibited the EGFR/AKT signaling pathway and showed an ability to improve the effectiveness of cisplatin against NSCLC and its resistant variants.
Overall, we observed that Acyclic Retinoid may hold significant promise as a therapeutic strategy for lung cancer, particularly for those patients who have developed resistance to traditional treatments. Its capability to enhance the effects of existing chemotherapy options could lead to better outcomes for patients battling this challenging disease.
We treated various types of lung cells—including standard cancer cell lines and those resistant to cisplatin—with ACR, both alone and alongside cisplatin. By examining cell viability, apoptosis (the process of programmed cell death), and changes in important cellular signals, we gathered insightful data on the potential of this treatment. The results were promising; ACR inhibited the EGFR/AKT signaling pathway and showed an ability to improve the effectiveness of cisplatin against NSCLC and its resistant variants.
Overall, we observed that Acyclic Retinoid may hold significant promise as a therapeutic strategy for lung cancer, particularly for those patients who have developed resistance to traditional treatments. Its capability to enhance the effects of existing chemotherapy options could lead to better outcomes for patients battling this challenging disease.
Read More
9
Vitamin A combined with SM effective
Combinational therapy of all-trans retinoic acid (ATRA) and sphingomyelin induces apoptosis and cell cycle arrest in B16F10 melanoma cancer cells.
Study relevance moderate
We explored the potential of all-trans retinoic acid (ATRA), a derivative of vitamin A, in treating melanoma. In our study, we combined ATRA with sphingomyelin (SM) to see if this pairing could enhance its effectiveness against aggressive melanoma cells.
We focused on an in vitro model using B16F10 melanoma cells and assessed how well this combination could promote cell death and stop the cells from growing. Our results highlighted that the combination of 123 μM of ATRA with 136 μM of SM was particularly effective, leading to a dramatic reduction in cell proliferation and significant apoptotic cell death.
This combination not only increased the expression of key genes that promote cell death, but it also caused a halt in the cell cycle, preventing cancer cells from continuing to grow. Moreover, our findings suggest that using ATRA alongside SM may provide a promising avenue for melanoma treatment while minimizing harm to normal, healthy cells.
We focused on an in vitro model using B16F10 melanoma cells and assessed how well this combination could promote cell death and stop the cells from growing. Our results highlighted that the combination of 123 μM of ATRA with 136 μM of SM was particularly effective, leading to a dramatic reduction in cell proliferation and significant apoptotic cell death.
This combination not only increased the expression of key genes that promote cell death, but it also caused a halt in the cell cycle, preventing cancer cells from continuing to grow. Moreover, our findings suggest that using ATRA alongside SM may provide a promising avenue for melanoma treatment while minimizing harm to normal, healthy cells.
Read More
User Reviews
USERS' SCORE
Good
Based on 23 Reviews
8.9
- All Reviews
- Positive Reviews
- Negative Reviews
9.5
Improved gastritis
The required amount of Vitamin A varies significantly depending on individual circumstances. Those with dry eye, asthma, gastrointestinal issues, or a family history of cancer may require more. I gradually increased my intake to 100,000 units for a year, which cleared my persistent red sore gastritis, eliminating the need for medication.
Read More
9.5
Healed cystitis
Vitamin A has been fantastic for me. Despite a family history of cancer, I was cautious about overdosing, so I started at 25,000 and moved to 50,000. My cystitis improved, corns softened, and irregular bleeding stopped. If I can heal without surgery, I will continue striving for 75,000 daily!
Read More
9.5
Improved eyesight
Following a high-protein, low-sugar diet and taking Vitamin A has improved my eyesight, and my wife's presbyopia has resolved. We take these supplements to prevent cancer due to a familial history, which is particularly important for our health.
10
Improved stability
I was advised by my doctor to take 225,000 IU of vitamin A daily due to a positive cancer marker. Since then, my numbers have stabilised. I've also been taking Vitamin C (5,000 IU) and Vitamin D (10,000 IU). Despite overdose concerns, I’ve experienced no issues after three years. My doctor believes high levels of vitamins A, C, and D can mitigate severe outcomes from both COVID-19 and cancer. I'm satisfied with the quality of NOW products.
Read More
9.5
Cancer protection
Vitamin A is vital for protecting against viral infections and improving mucous membranes, vital for both cancer treatment and general health. It accelerates wound healing and supports cell metabolism. I was advised to use it for psoriasis; the dosage and quality seem advantageous.
